V
BBH
VanEck Biotech ETF
190.04
+3.87+2.08%After Hours: 190.04 0.00 0.00%16:10 04/08 EDT
OPEN/PREV CLOSE190.42/186.17
TODAY RANGE188.24-190.42
VOL6.41K
TOTAL ASSET368.19M
52 WEEK RANGE134.67-202.91
% TURNOVER0%
NAV186.28
EXPENSE RATIO(NET)0.35%
1Y RETURN(CUM.)29.32%
DIVIDEND0.9565
DIV YIELD0.50%
EX-DATE12/22/2025
% RANGE1.17%
INCEPTION DATE12/20/2011
BETA--
LOT SIZE1
LIPPER RATING★★★☆☆
News
Seeking Alpha·4d ago
CDT Insider Sentiment March 2026: The Probability Race And Barbell Strategies
Seeking Alpha·6d ago
Biotech Is Holding Steady In 2026
Seeking Alpha·03/31 01:10
Oil Shock Meets Asset Price Deflation
Seeking Alpha·03/20 07:05
Finally Coming Into View? 'Old-Economy' Stocks Show Their Colors
Seeking Alpha·03/19 05:10
Q4 2025 Earnings: AI Disruption Vs. Traditional Fundamentals
NASDAQ·03/17 09:05
The Zacks Analyst Blog Highlights IBB, XBI, BBH and GNOM
NASDAQ·03/16 13:39
Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave
Benzinga·03/10 13:24
Vertex's New Kidney Drug Delivers Big Trial Win, Stock Jumps
NASDAQ·03/10 10:20
Should You Invest in the VanEck Biotech ETF (BBH)?
Seeking Alpha·03/08 18:42
The K-Shaped Consumer Economy: GLP-1s, AI And The Future Of Consumer Spending
Seeking Alpha·03/06 09:00
The Trump Administration's Affordability Plan
Seeking Alpha·03/02 18:04
AAPL, AA, BKR, and AMGN are among the top stocks for momentum, says Oppenheimer
Seeking Alpha·02/26 11:56
Q1 Active Management Pulse: Positioning Broadens Beyond AI Leaders
Seeking Alpha·02/19 21:36
Most investors expect the Supreme Court to block Trump tariffs in 2026, Goldman Sachs says
Seeking Alpha·02/19 03:38
Incyte Remains Undervalued As Opzelura And Niktimvo Scale
Same Industry
Name/Symbol
Change%
Price
No data yet, let's see others